Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 148 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Tamoxifen Clear all

Conditions: Cognition, Aging
Interventions: tamoxifen, raloxifene; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 65 Years and older · Female only
Enrollment: 1,498 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2008
U.S. locations: 127
States / cities: Phoenix, Arizona • Tucson, Arizona • Camp Pendleton, California + 102 more

Conditions: Breast Cancer
Interventions: microarray analysis, polymerase chain reaction, protein expression analysis, diagnostic laboratory biomarker analysis, fluorescent antibody technique, immunohistochemistry staining method, immunologic technique; Genetic · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Female only
Enrollment: 957 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Hot Flashes, Hot Flushes
Interventions: soy protein, isoflavones, Tamoxifen, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 14
States / cities: Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more

Conditions: Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions: citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy; Drug · Genetic · Other + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more

Conditions: Solid Tumor
Interventions: MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more

Conditions: Melanoma (Skin)
Interventions: cisplatin, sorafenib tosylate, tamoxifen citrate, adjuvant therapy; Drug · Procedure
Lead sponsor: San Diego Pacific Oncology & Hematology Associates; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Metastatic Breast Cancer
Interventions: Palbociclib, Tamoxifen; Drug
Lead sponsor: Oana Danciu, MD; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Chicago, Illinois • Lansing, Michigan • Minneapolis, Minnesota + 4 more

Conditions: Breast Cancer
Interventions: arzoxifene hydrochloride, tamoxifen citrate; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 6 more

Conditions: Breast Cancer
Interventions: hCG; Drug
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Tamoxifen; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Chicago, Illinois • Buffalo, New York

Conditions: ERα+ Breast Cancer, ESR1 Gene Mutation
Interventions: Tamoxifen, FES PET/CT; Drug · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 19 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Hodgkin's Disease, Breast Cancer
Interventions: Tamoxifen; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Endometrial Cancer
Interventions: medroxyprogesterone, tamoxifen citrate, adjuvant therapy; Drug · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2009
U.S. locations: 122
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 84 more

Conditions: Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Interventions: Infigratinib, Tamoxifen, Omnipaque 350, Iopamidol, Computed tomography (CT); Drug · Diagnostic Test
Lead sponsor: Jennifer Lee Caswell-Jin; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions: PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide, Giredestrant, Tamoxifen; Drug · Combination Product · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 14
States / cities: Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more

Conditions: Breast Cancer, Ductal Carcinoma in Situ
Interventions: Not listed
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Neoplasm Metastasis, Osteosarcoma
Interventions: OncoLAR® (Registered Trademark), tamoxifen; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Desmoid Tumor
Interventions: tamoxifen citrate, sulindac, laboratory biomarker analysis; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Monrovia, California

Conditions: Breast Cancer, Fertility
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 25 Years and older · Female only
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: suberoylanilide hydroxamic acid (SAHA, Vorinostat), tamoxifen citrate (Tamoxifen); Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 8
States / cities: San Francisco, California • Boynton Beach, Florida • Orlando, Florida + 5 more

Conditions: Breast Cancer
Interventions: letrozole, tamoxifen citrate, conventional surgery, neoadjuvant therapy; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: Female only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions: Exemestane, Exemestane and tamoxifen; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer
Interventions: Aromatase inhibitors or tamoxifen; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Cognition in the Study of Tamoxifen and Raloxifene

Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer

Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women

Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity

A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma

Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

Investigating the Impact of Tamoxifen Therapy on Ovarian Aging

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer